Skip to main content
SpringerLink
Log in

Economic impact of infections in patients with cancer

  • Chapter
Management of Infectious Complications in Cancer Patients

Part of the book series: Cancer Treatment and Research ((CTAR))

  • 168 Accesses

Abstract

The cost of caring for patients with cancer has been reported to total over $100 billion dollars per year [1]. Patients who have cancer have high utilization rates of medical care and have more medical interventions than patients with non-cancer-related diagnoses [2]. One study, that examined the costs associated with the treatment of cancer found treatment costs to be $29,708 a year [3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Leake AR. The economic impact of cancer. Nurse Practioner Forum, No. 4 (December), 1995, pp. 207–214.

    Google Scholar 

  2. Munoz E, Chalfin D, Rosner F, et al. Hospital costs, cancer patients and medical diagnosis-related groups. Onclogy 1988;45:401–404.

    Article  CAS  Google Scholar 

  3. Bloom BS, Knorr, Evans AE. The epidemiology of disease expense. The costs of caring for children with cancer. JAMA 1985;253:2393–2397.

    Article  PubMed  CAS  Google Scholar 

  4. Haley RW, Schaberg DR. Extra charges and prolongation of stay attributable to nosocomial infections: A prospective interhospital compatison. Am J Med 1981;70:51–57.

    Article  PubMed  CAS  Google Scholar 

  5. Shulkin DJ, Kinosian B, Glick H, Glen-Puschett C, Daly J, Eisenberg JM. The economic impact of infections. An analysis of hospital costs and charges in surgical patients with cancer. Arch Surg 1993:128:449–452.

    PubMed  CAS  Google Scholar 

  6. Montero MC, Valdivia ML, Carvajal E, et al. Economic study of neutropenia induced by myelotoxic chemotherapy. Pharm World Sci 1994;16:187–192.

    Article  PubMed  CAS  Google Scholar 

  7. DeVita, Hellman, Rosenburg (eds). Cancer: Principles and Practice of Oncology, 4th ed. 1993.

    Google Scholar 

  8. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993;85:460–474.

    Google Scholar 

  9. Weeks JC, Tierney MR, Weinstein MC. Cost-effectiveness of prophylactic intravenous immune globulin in chronic lymphoctic leukemia. N Engl J Med 1991;325:81–86.

    Article  PubMed  CAS  Google Scholar 

  10. Lyman GH, Lyman CG, Sanderson RA, Balducci L. Decision analysis of hematopoietic grwoth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993;85:488–493.

    Article  PubMed  CAS  Google Scholar 

  11. Glaspy JA, Bleecker G, Crawford J, et al. The impact of therapy with filgrastim (recombinant granulocyte colony-stumulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer 1993;29A(Suppl.):S23–S30.

    Article  PubMed  Google Scholar 

  12. Riikonen P, Saarrian UM, Makipernaa A, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: A double blind placebo-controlled study in children. J Pediatr Infect Dis 1994:13:197–202.

    Article  CAS  Google Scholar 

  13. Mayordomo JI, Rivera F, Diaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995;87:803–808.

    Article  PubMed  CAS  Google Scholar 

  14. Lawless GD. Health resources utilization in ABMT with and without G-CSF in stage III/IV breast cancer patients. Oncology 1995(Suppl.):107–110.

    Google Scholar 

  15. Morstyn G, Foote M, Lieschke GJ. Hematopoietic growth factors in cancer chemotherpay. Cancer Chemother Biol Response Modif 1996;16:295–314.

    PubMed  CAS  Google Scholar 

  16. Rosenshein MS, Farewell VT, Prire TH, et al. The cost effectiveness therapeutic and prophylactic leukocyte transfusions. N Engl J Med 1980;302:1058–1062.

    Article  PubMed  CAS  Google Scholar 

  17. Guiguet M, Rekacewicz C, Leclerq B, et al. Effectiveness of simple measures to control an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections in an intensive care unit. Infect Control Hosp Epidemiol 1990;ll:23–26.

    Article  Google Scholar 

  18. Sawamura N, Akagi E, Narakoa I, Masunaga Y, Yokoyama S, Saijo N. Significance of the bioclean room during treatment of lung cancer. Jpn J Cancer Chemother 1984;11:253–259.

    CAS  Google Scholar 

  19. Ueda T, Shibata H, Nakamura H, et al. Efficacy of laminar air flow room with or without clean nursing for preventing infection in patients with acute leukemia. Jpn J Clin Oncol 1983;13(Suppl. 1):151–157.

    PubMed  Google Scholar 

  20. Cimino MA, Rotstein CM, Moser JE. Assessment of cost-effective antibiotic therapy in the management of infections in cancer patients. Ann Pharmacother 1994;28:105–111.

    PubMed  CAS  Google Scholar 

  21. Counsell R. Pratt J, Williams MV. Chemotherapy for germ cell tumors: Prophylactic ciprofloxacin reduces the incidence of neutropenic fever. Clin Oncol 1994;6:232–236.

    Article  CAS  Google Scholar 

  22. Velasco E. Costa MA, Martins CA, Nucci M. Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. Am J Clin Oncol 1995;18:429–435.

    Article  PubMed  CAS  Google Scholar 

  23. Rubinstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71:3640–3646.

    Article  Google Scholar 

  24. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995;172:1035–1041.

    PubMed  CAS  Google Scholar 

  25. Shulin D. Critical pathways. In: Kelley. ed. Textbook of Internal Medicine, 3rd ed. Philadelphia: Lippincott-Raven, 1997, pp. 237–241.

    Google Scholar 

  26. Mullen CA, Buchanan GR. Early hospital discharge of children with cancer treated for fever and neutropenia: Identification and managment of the low-risk patient. J Clin Oncol 1990;8:1998–2004.

    PubMed  CAS  Google Scholar 

  27. Tomiak A, Yau J, Huan S, et al. Duration of intravenous antibiotic and hospital stay for patients with febrile neutropenia after chemotherapy: Experience of Ottawa Regional Cancer Center. Proc Ann Mtg Am Soc Clin Oncol 1993;12:A1500.

    Google Scholar 

  28. El-Deiry W, Morris L. High cost of hospital admissions for cancer patients at low risk to develop complications from febrile neutropenia. Proc Ann Mtg Am Soc Clin Oncol 1993;12:A1606.

    Google Scholar 

  29. Bash RO, Katz JA, Cash JV, et al. Safety and cost-effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994;74:189–196.

    Article  PubMed  CAS  Google Scholar 

  30. Mor V, Stalker MZ, Gralla R, et al. Day hospital as an alternative to inpatient care for cancer patients: A random assignment trial. J Clin Epidemiol 1988;41:771–785.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. David J. Shulkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lawrence J. Anastasi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northwestern Medical University School, Chicago, Illinois

    Gary A. Noskin (Associate Professor of Medicine, Medical Director) (Associate Professor of Medicine, Medical Director)

  2. Infection Control Healthcare Epidemiology, Northwestern Memorial Hospital, Chicago, Illinois

    Gary A. Noskin (Associate Professor of Medicine, Medical Director) (Associate Professor of Medicine, Medical Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Kluwer Academic Publishers, Boston

About this chapter

Cite this chapter

Shulkin, D.J., Anastasi, L.J. (1998). Economic impact of infections in patients with cancer. In: Noskin, G.A. (eds) Management of Infectious Complications in Cancer Patients. Cancer Treatment and Research. Springer, Boston, MA. https://doi.org/10.1007/978-0-585-38152-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-0-585-38152-7_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-7923-8150-1

  • Online ISBN: 978-0-585-38152-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation